High Vista Strategies LLC Syndax Pharmaceuticals Inc Transaction History

High Vista Strategies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$19.71 - $24.57 $424,139 - $528,721	21,519 New	21,519 $512,000
Q3 2023 Nov 14, 2023	SELL	$14.52 - $21.77 $59,328 - $88,952	-4,086 Reduced 12.17%	29,490 $428,000
Q2 2023 Aug 14, 2023	BUY	$19.35 - $22.31 $154,258 - $177,855	7,972 Added 31.14%	33,576 $702,000
Q1 2023 May 15, 2023	BUY	$20.66 - $28.98 $143,442 - $201,208	6,943 Added 37.21%	25,604 $540,000
Q4 2022 Feb 14, 2023	SELL	$20.64 - $26.24 $380,663 - $483,944	-18,443 Reduced 49.71%	18,661 $474,000
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $686,795 - $919,808	37,104 New	37,104 $892,000
Q1 2022 May 16, 2022	SELL	$14.84 - $22.15 $569,069 - $849,386	-38,347 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.23 - $22.47 $110,219 - $162,615	-7,237 Reduced 15.88%	38,347 $839,000
Q3 2021 Nov 15, 2021	SELL	$13.87 - $19.8 $30,930 - $44,154	-2,230 Reduced 4.66%	45,584 $872,000
Q2 2021 Aug 16, 2021	BUY	$13.42 - $25.18 $173,668 - $325,854	12,941 Added 37.11%	47,814 $821,000
Q1 2021 May 17, 2021	BUY	$19.28 - $24.59 $672,351 - $857,527	34,873 New	34,873 $779,000

228

88.4M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.